Business Monitor International


Bangladesh Pharmaceuticals & Healthcare Report

Published 06 March 2014

  • 111 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Bangladesh Pharmaceuticals & Healthcare Report

BMI View: While economic growth is boosting demand for pharmaceuticals in Bangladesh, income inequality continues to drive the purchase of counterfeit medicines. In November 2013, the government vowed to continue fighting the growing industry of substandard, counterfeit and life-endangering medicines - a positive development for patients. C ounterfeiting hijacks brand s and infringes legitimate pharmaceutical manufacturers ' patent and trademark rights - affecting their revenue - earning abilities in the Bangladeshi pharmaceutical market.

Headline Expenditure Projections

  • Pharmaceuticals: BDT124.25bn (US$1.52bn) in 2012 to BDT138.80bn (US$1.76bn) in 2013; +11.7% in local currency terms and +16.1% in US dollar terms.

  • Healthcare: BDT349.08bn (US$4.27bn) in 2012 to BDT399.56bn (US$5.07bn) in 2013; +14.5% in local currency terms and +18.9% in US dollar terms.

Risk/Reward Ratings: While geographic diversification and investment into the pharmaceutical and healthcare sectors of emerging economies such as Bangladesh may be a favourable strategy for any multinational pharmaceutical company, it is vital that a company recognises both the rewards and the risks present in a market. For Q114, Bangladesh stands at 16th position out of the 18 regional markets surveyed. Its overall rating of 40 out of 100 remains considerably lower than the average for the region.

Key Trends And Developments

In October 2013, it was reported that the number of heart disease patients and spending on treatment have been rising sharply in Bangladesh. For example, data from the National Heart Foundation Hospital and Research Institute (NHFHRI) in Dhaka suggest that a total 18,610 patients were admitted in 2012, a growth of 13% year-on-year from 16,471 patients admitted in 2011.

Bangladesh's Dhaka Medical College and Hospital opened its new 10-storey, 600-bed second building in October 2013. Another Bangladeshi medical college, the Faridpur Medical College and Hospital, opened its new...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Business Environment
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Bangladesh Pharmaceutical Sales, Historical Data And Forecasts
14
Healthcare Market Forecast
16
Table: Bangladesh Healthcare Expenditure Trends, Historical Data And Forecasts
17
Table: Bangladesh Government Healthcare Expenditure Trends, Historical Data And Forecasts
17
Table: Bangladesh Private Healthcare Expenditure Trends, Historical Data And Forecasts
18
Prescription Drug Market Forecast
19
Table: Bangladesh Prescription Drug Market Indicators, Historical Data And Forecasts
20
Patented Drug Market Forecast
21
Table: Bangladesh Patented Drug Market Indicators, Historical Data And Forecasts
22
OTC Medicine Market Forecast
23
Table: Bangladesh Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts
24
Generic Drug Market Forecast
24
Table: Bangladesh Generics Drug Market Indicators, Historical Data And Forecasts
25
Pharmaceutical Trade Forecast
26
Table: Bangladesh Pharmaceutical Trade Data And Forecasts (US$mn)
28
Table: Bangladesh Pharmaceutical Trade Data And Forecasts (BDTmn)
28
Other Healthcare Data
29
Key Risks To BMI's Forecast Scenario
30
Macroeconomic Forecasts
31
Economic Analysis
31
Table: Bangladesh - Economic Activity
36
Industry Risk Reward Ratings
37
Asia Pacific Risk/Reward Ratings
37
Bangladesh Risk/Reward Ratings
43
Rewards
43
Risks
43
Market Overview
45
Industry Trends And Developments
46
Epidemiology
46
Healthcare Sector
54
Healthcare Sector Financing
58
Healthcare Infrastructure
59
Table: Hospital And Beds, 2002-2006
60
Table: Public Primary Care Facilities, 1994-2004
60
Table: Medical Personnel by Type, 1995-2006
61
Research & Development
62
Table: Suggestions Made By University Of Dhaka's Faculty Of Pharmacy To Improve Pharmaceutical Research
63
Clinical Trials
64
Regulatory Development
65
Regulatory Regime
65
Table: Steps To Establish A Pharmaceutical Manufacturing Unit And Obtain A Drug Manufacturing Licence
67
Counterfeit Drugs
67
Intellectual Property
68
Pricing & Reimbursement
69
Competitive Landscape
72
Pharmaceutical Industry
72
Domestic Pharmaceutical Industry
73
Foreign Pharmaceutical Industry
74
Contract Manufacturing
74
Foreign Company Developments
76
Local Company Developments
78
Distribution Sector
79
Company Profile
81
Eskayef
81
Square Pharmaceuticals
84
Renata
88
Beximco Pharmaceuticals
91
Sanofi
95
Novartis
97
Demographic Forecast
100
Table: Bangladesh's Population By Age Group, 1990-2020 ('000)
101
Table: Bangladesh's Population By Age Group, 1990-2020 (% of total)
102
Table: Bangladesh's Key Population Ratios, 1990-2020
103
Table: Bangladesh's Rural And Urban Population, 1990-2020
103
Glossary
104
Methodology
106
Pharmaceutical Expenditure Forecast Model
106
Healthcare Expenditure Forecast Model
106
Notes On Methodology
107
Risk/Reward Ratings Methodology
108
Ratings Overview
109
Table: Pharmaceutical Risk/Reward Ratings Indicators
109
Indicator Weightings
110

The Bangladesh Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Bangladesh Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Bangladeshi pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Bangladesh to test other views - a key input for successful budgeting and strategic business planning in the Bangladeshi pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Bangladeshi pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Bangladesh.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc